US20170320878A1 - Method for preparation of fluoro, chloro and fluorochloro alkylated compounds by homogeneous catalysis - Google Patents

Method for preparation of fluoro, chloro and fluorochloro alkylated compounds by homogeneous catalysis Download PDF

Info

Publication number
US20170320878A1
US20170320878A1 US15/522,336 US201515522336A US2017320878A1 US 20170320878 A1 US20170320878 A1 US 20170320878A1 US 201515522336 A US201515522336 A US 201515522336A US 2017320878 A1 US2017320878 A1 US 2017320878A1
Authority
US
United States
Prior art keywords
alkyl
group
compsubst
independently
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US15/522,336
Other versions
US9809596B1 (en
Inventor
Christoph Taeschler
Florencio Zaragoza Doerwald
Stefan Ellinger
Matthias Beller
Helfried Neumann
Lin He
Kishore Natte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arxada AG
Original Assignee
Lonza AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza AG filed Critical Lonza AG
Priority to US15/522,336 priority Critical patent/US9809596B1/en
Assigned to LONZA LTD. reassignment LONZA LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ZARAGOZA DOERWALD, FLORENCIO, HE, LIN, TAESCHLER, CHRISTOPH, BELLER, MATTHIAS, NATTE, Kishore, ELLINGER, STEFAN, NEUMANN, HELFRIED
Application granted granted Critical
Publication of US9809596B1 publication Critical patent/US9809596B1/en
Publication of US20170320878A1 publication Critical patent/US20170320878A1/en
Assigned to LONZA SOLUTIONS AG reassignment LONZA SOLUTIONS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LONZA LTD (ALSO KNOWN AS LONZA AG)
Assigned to ARXADA AG reassignment ARXADA AG CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: LONZA SOLUTIONS AG
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/10—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22—Organic complexes
    • B01J31/2204—Organic complexes the ligands containing oxygen or sulfur as complexing atoms
    • B01J31/2208—Oxygen, e.g. acetylacetonates
    • B01J31/2226—Anionic ligands, i.e. the overall ligand carries at least one formal negative charge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B39/00—Halogenation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00—Preparation of halogenated hydrocarbons
    • C07C17/26—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton
    • C07C17/272—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by addition reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00—Preparation of halogenated hydrocarbons
    • C07C17/26—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton
    • C07C17/272—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by addition reactions
    • C07C17/275—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by addition reactions of hydrocarbons and halogenated hydrocarbons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C22/00—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom
    • C07C22/02—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings
    • C07C22/04—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings containing six-membered aromatic rings
    • C07C22/08—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings containing six-membered aromatic rings containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
    • C07C41/30—Preparation of ethers by reactions not forming ether-oxygen bonds by increasing the number of carbon atoms, e.g. by oligomerisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/34—Separation; Purification; Stabilisation; Use of additives
    • C07C41/46—Use of additives, e.g. for stabilisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/69—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by addition to carbon-to-carbon double or triple bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/80—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/12—Radicals substituted by halogen atoms or nitro or nitroso radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Definitions

  • FCLALKYLHALIDE is a compound of formula (III);
  • COMPSUBST-I is unsubstituted or substituted
  • said C 1-4 alkyl substituent of COMPSUBST-I is unsubstituted or substituted with 1, 2 or 3 identical or different, substituents selected from the group consisting of halogen;
  • the fluoro, chloro or fluorochloro alkylated compound is called compound ALKYLCOMPSUBST.
  • mol equivalents are based on the molar amount of COMPSUBST.
  • the reaction mixture was extracted with water and ethyl acetate (5 times, each time with 3 mL). The organic layers were washed with brine, dried over Na 2 SO 4 , and evaporated to yield the crude product. The yield was 81%.
  • the autoclave was cooled down to room temperature and the pressure was released.
  • the base was Cs 2 CO 3 .

Abstract

The invention discloses a method for preparation of fluoro, chloro and fluorochloro alkylated compounds by homogeneous Pd catalyzed fluoro, chloro and fluorochloro alkylation with fluoro, chloro and fluorochloroalkyl halides in the presence of di(1-adamantyl)-n-butylphosphine and in the presence of 2,2,6,6-tetramethylpiperidine 1-oxyl.

Description

    RELATED APPLICATIONS
  • This application is the national stage entry of International Patent Application No. PCT/EP2015/075763 having a filing date of Nov. 5, 2015, which claims the filing benefit of U.S. Provisional Application No. 62/076,618, having a filing date of Nov. 7, 2014, European Patent Application No. 14192280.7, having a filing date of Nov. 7, 2014, European Patent Application No. 15181003.3, having a filing date of Aug. 13, 2015, and European Patent Application No. 15181019.9, having a filing date of Aug. 14, 2015, all of which, are incorporated herein by reference in their entirety.
    • FIELD OF THE INVENTION
  • The invention discloses a method for preparation of fluoro, chloro and fluorochloro alkylated compounds by homogeneous Pd catalyzed fluoro, chloro and fluorochloro alkylation with, fluoro, chloro and fluorochloro alkyl halides in the presence of di(1-adamantyl)-n-butylphosphine and in the presence of 2,2,6,6-tetramethylpiperidine 1-oxyl.
    • BACKGROUND OF THE INVENTION
  • Organophlorine chemistry plays an important role in medicinal, agricultural, and material sciences and fields, Fluoroalkyl groups have strong effects such as high stability and lipophilicity, in addition, longer fluoroalkyl groups have high water and oil resistance and low function.
  • Loy, R. N., et al., Organic Letters 2011, 13, 2548-2551, discloses Pd-catalyzed coupling of CF3-I with benzene in 26% GC yield.
  • According to Table 1 entry 10 the coupling of C6F13I provided 81% yield. But a repetition of this experiment with the bromide instead of the iodide provided less than 1% yield, see Comparative Example 11 herein.
  • There was a need tor a homogenous catalyzed method for the preparation of fluoro, chloro and fluorochloro alkylated compounds by direct C-H trifluoromethylation, which provides high yields but does not need the assistance of a directing group or of electron rich aromatic compounds. The method should be applicable to a wide variety of substrates and should be compatible with a wide variety of functional groups. Furthermore the method should not be restricted to iodides as alkylating agents only, but should also work with other halides. And the method should work not only with perfluorinated alkyl iodides, but also with fluorinated, chlorinated and fluorochlorinated alkyl halides, especially for fluorinated alkyl halides.
  • Unexpectedly the presence of di(1-adamanlyl)-n-butylphosphine and 2,2,6,6-tetramethylpiperidine 1-oxyl together with a soluble Pd based catalyst meets these requirements. No dialkylated products are observed.
  • In this text, the following meanings are used, if not otherwise stated:
  • Ac acetate;
  • alkyl linear or branched alkyl;
  • BuPAd2 CAS 321921-71-5, di(1-adamantyl)-n-butylphosphine;
  • DMSO dimethylsulfoxide;
  • eq. equiv equivalent;
  • halide F-, Cl-, Br- or I-, preferably Cl-, Br, and I-, more preferably Br- and I-;
  • halogen F, Cl, Br or I; preferably F, Cl or Br; more preferably F or Cl;
  • “linear” and “n-” are used synonymously with respect to the respective isomers of alkanes;
  • MTBE methyl tert-butyl ether;
  • RT room temperature, it is used synonymously with the expression ambient temperature;
  • TEA triethylamine;
  • TEMPO CAS 2564-83-2,2,2,6,6-tetramethylpiperidine 1-oxyl;
  • TFA trifluoroacetate;
  • “wt %”, “% by weight” and “weight-%” are used synonymously and mean percent by weight.
    • SUMMARY OF THE INVENTION
  • Subject of the invention is a method for the preparation of a fluoro, chloro or fluorochloro alkylated compound by a reaction of a compound COMPSUBST with a compound FCLALKYLFIALIDE by homogeneous catalysis using a catalyst CAT
  • in the presence of BuPAd2 and
  • in the presence of TEMPO and
  • in the presence of a compound BAS,
  • BAS is selected horn the group consisting of Cs2CO3, CsHCO3, NEt3, and mixtures thereof;
  • FCLALKYLHALIDE is a compound of formula (III);

  • R3-X  (III)
  • X is Cl, Br or I;
  • R3 is C1-20 alkyl or a C1-20 alkyl, wherein in the alkyl chain at least one of the hydrogens is substituted by F or Cl;
  • CAT is selected from the group consisting of Pd(OAc)2, Pd(TFA)2, and mixtures thereof;
  • COMPSUBST is selected from the group consisting of a compound COMPSUBST-I, ethene, cyclohexene, ethine, and polystyrene;
      • the ethene and the cyclohexene being unsubstituted or substituted by 1, 2 or 3 substitutents selected from the group consisting of C1-10 alkyl, C3-8cycloalkyl, C1-4 alkoxy, N(R10)R11, CN, NO, NO2, F, Cl, Br, I, CF3, (CH2)m-C(O)Y1, S(O)2R50, CH═C(H)R28, C≡C-R24, benzyl, phenyl, naphthyl and morpholine;
      • the ethine being unsubstituted or substituted by 1 substituted selected from the group consisting of C1-10 alkyl, C3-8 cycloalkyl, C1-4 alkoxy, N(R10)R11, CN, NO, NO2, F, Cl, Br, I, CF3, (CH2)m-C(O)Y1, S(O)2R50, CH═C(H)R28, C≡C-R24, benzyl, phenyl and naphthyl;
  • COMPSUBST-1 contains a ring RINGA;
  • RINGA is an unsaturated or aromatic, 5 or 6 membered carbocyclic or heterocyclic ring,
      • when RINGA is a heterocyclic ring, then RINGA has 1, 2 or 3 identical or different endocyclic heteroatoms independently from each other selected from the group consisting of N, O and S,
      • when RINGA is a 5 membered ring, then RINGA is unsubstituted or substituted by 1, 2, 3 or 4 identical or different substituents,
      • when RINGA is a 6 membered ring then RINGA is unsubstituted or substituted by 1, 2, 3, 4 or 5 identical or different substituents,
      • any of said substituents of RINGA is independently from any other of said substituted of RINGA selected from the group consisting of C1-10 alkyl, C3-8 cycloalkyl, C1-4 alkoxy, OH, N(R10)R11, CN, NH—OH, NO, NO2, F, Cl, Br, I, CF3, (CH2)m-C(O)Y1, S(O)2R50, CH═C(H)R28C≡C-R24 , benzyl phenyl and naphthyl;
      • RINGA can be condensed with a ring RINGB, RINGB is a 5 or 6 membered carbocyclic or heterocyclic ring,
      • when RINGB is a heterocyclic ring, is contains 1, 2 or 3 identical or different endocyclic heteroatoms independently from each other selected from the group consisting of N, O and S;
      • RINGB is unsubstituted or substituted with 1, 2 or 3 in case of RINGB being a 5 membered ring, with 1, 2, 3 or 4 in case of RINGB being a 6 membered ring, identical or different substitutents independently from each other selected from the group consisting of C1-10 alkyl, C3-8 cycloalkyl, C1-4alkoxy, OH, N(R17)R18, CN, NH—OH, NO, NO2, F, Cl, Br, I, CF3) (CH2)n-C(O)Y2, S(O)2R51, CH═C(H)R38, C≡C-R34, benzyl, phenyl and naphthyl;
      • any of said C1-10 alkyl substituent of RINGA or RINGB is unsubstituted or substituted with 1, 2, 3, 4 or 5 identical or different substituents selected from the group consisting of halogen, OB, O—C(O)—C1-5 alkyl, O—C1-10alkyl, S—C1-10 alkyl, S(O)—C1-10 alkyl, S(O2)—C1-10 alkyl, O—C1-6 alkylen-O—C1-6 alkyl, C3-8 cycloalkyl and 1,2,4-triazolyl;
      • any of said benzyl, phenyl and naphthyl substituent of RINGA or RINGB is independently from each other unsubstituted or substituted with 1, 2, 3, 4 or 5 identical or different substituents selected from the group consisting of halogen, C1-4 alkoxy, NO2 and CN;
  • m, n and q are identical or different and independently from each other 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
  • Y1, Y2 and R13 are identical or different; and independently from each other selected from the group consisting of H, OH, C(R14)(R15)R16, C1-6, alkyl, O—C1-6 alkyl phenyl, benzyl O-phenyl, O—C1-6alkylen-O—C1-6alkyl and N(R19)R20;
  • R14, R15 and R16 are identical or different and independently from each other selected from the group consisting of H, F, Cl and Br;
  • R10, R11, R17, R18, R19 and R20 are identical or different and are independently from each other H or C1-6 alkyl, or R10 and R11, R17 and R18 or R19 and R20 represent together a tetramethylene or a pentamethylene chain;
  • R50 and R51 are identical or different and independently from each other selected from the group consisting of OH, C1-6alkyl and C1-6alkoxy;
  • R24, R34, R28 and R38 are identical or different and independently from each other selected from the group consisting of H, C1-10 alkyl, C(R25)(R26)-O—R27;
  • R25, R26 and R27 are identical or different and independently from each other selected from the group consisting of H and C1-10alkyl.
    • DETAILED DESCRIPTION OF THE INVENTION
  • Preferably, RINGA is a carbocyclic unsaturated ring, a carbocyclic aromatic ring, a heterocyclic unsaturated ring or a heterocyclic aromatic ring.
  • Preferably, COMPSUBST is selected from the group consisting of compound COMPSUBST-I, ethene, cyclohexene, ethine, and polystyrene;
      • the ethene and the cyclohexene being unsubstituted or substituted by 1 or 2 substitutents selected from the group consisting of C1-10 alkyl, C3-6 cycloalkyl, C1-4 alkoxy, N(R10)R11, CN, F, Cl, Br, I, CF3, (CH2)m-C(O)Y1, S(O)2R50, benzyl, phenyl, naphthyl and morpholine;
      • the ethine being unsubstituted or substituted by 1 substituted selected from the group consisting of C1-10 alkyl, C3-6 cycloalkyl, C1-4 alkoxy, N(R10)R11, CN, F, Cl, Br, I, CF3, (CH2)m-C(O)Y1, S(O)2R50, benzyl, phenyl and naphthyl;
  • with COMPSUBST-I being selected from the group consisting of
  • Figure US20170320878A1-20171109-C00001
  • with COMPSUBST-I being unsubstituted or substituted
      • by 1, 2, 3 or 4 in case of COMPSUBST-I being a monocyclic compound with 5 endocyclic atoms,
      • by 1,2, 3, 4 or 5 in case of COMPSUBST-I being a monocyclic compound with 6 endocyclic atoms,
      • by 1, 2, 3, 4, 5 or 6 in case of COMPSUBST-I being a bicyclic compound wherein a 5-membered and a 6-membered ring are ortho-fused,
      • by 1, 2, 3, 4, 5, 6 or 7 in case of COMPSUBST-I being a bicyclic compound wherein two 6membered rings are ortho-fused.
      • identical or different substituents independently from each other selected from the group consisting of C1-10 alkyl, C3-8 cycloalkyl, C1-4 alkoxy, OH, C(H)═O, N(R10)R11, CN, NH—OH, NO, NO2, F, Cl, Br, I, CF3, (CH2)m-C(O)Y1, S(O)2R50, CH═C(H)R28, C≡C-R24, benzyl, phenyl and naphthyl;
  • said C1-10 alkyl substituent of COMPSUBST-I is unsubstituted or substituted with 1, 2, 3, 4 or 5 identical or different substituents selected from the group consisting of halogen, OH, O—C(O)—C1-5 alkyl, O—C1-10 alkyl, S—C1-10 alkyl, S(O)—C1-10 alkyl, S(O2)—C1-10 alkyl, O—C1-6 alkylen-O—C1-6 alkyl, C1-6 cycloalkyl and 1,2,4-triazolyl;
  • said benzyl, phenyl and naphthyl substituent of COMPSUBST-I is independently from each other unsubstituted or substituted with 1, 2, 3, 4 or 5 identical or different substituents selected from the group consisting of halogen, C1-4 alkoxy, NO2 and CN;
  • R10, R11, m, n, Y1, Y2, R28, R50 and R24 are defined as above, also with all their embodiments.
  • Preferably, m, n and q are identical or different and independently from each other 0, 1, 2, 3 or 4:
  • more preferably, m, n and q are 0 or 4.
  • In another embodiment, Y1, Y2 and R13 are identical or different and independently from each other selected from the group consisting of H, OH, C(R14)(R15)R16, C2-6 alkyl, O—C1-6 alkyl, phenyl, benzyl, O-phenyl, O—C1-6 alkylen-O—C1-6 alkyl and N(R19)R20.
  • Preferably, Y1, Y2 and R13 are identical or different and independently from each other selected from the group consisting of H, OH, C1-2 alkyl, and O—C1-2 alkyl.
  • More preferably, COMPSUBST-I is unsubstituted or substituted
      • by 1, 2 or 3 in case of COMPSUBST-I being a monocyclic compound with 5 endocyclic atoms,
      • by 1, 2, 3, 4 or 5 in ease of COMPSUBST-I being a monocyclic compound with 6 endocyclic atoms,
      • by 1, 2, 3, 4 or 5 in case of COMPSUBST-I being a bicyclic compound wherein a 5-membered and a 6-membered ring are ortho-fused,
      • by 1, 2, 3 or 4 in case of COMPSUBST-I being a bicyclic compound wherein two 6-membered rings are ortho-fused,
      • identical or different substituents independently from each other selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, OH, C(H)═O, N(R10)R11, CN, F, Cl, Br, CF3, (CH2)m-C(O)Y1, and S(O)2R50;
  • said C1-4 alkyl substituent of COMPSUBST-I is unsubstituted or substituted with 1, 2 or 3 identical or different, substituents selected from the group consisting of halogen;
  • with R10, R11, Y1 and R50 as defined above, also with all their embodiments.
  • Especially, COMPSUBST is selected from the group consisting of benzene, pyrazole,
  • Figure US20170320878A1-20171109-C00002
    Figure US20170320878A1-20171109-C00003
    Figure US20170320878A1-20171109-C00004
  • compound of formula (VI), ethene, cyclohexene, ethine, and polystyrene;
  • Y is C1-6 alkyl;
  • the ethene and the cyclohexene being unsubstituted or substituted by 1 or 2 substitutents selected from the group consisting of C1-10 alkyl, C1-4 alkoxy, N(R10)R11, CN, F, Cl, Br, I, CF3, (CH2)m-C(O)Y1, benzyl, phenyl and morpholine;
  • the ethine being unsubstituted or substituted by 1 substituted selected from the group consisting of C1-10 alkyl, C1-4 alkoxy, N(R10)R11, CN, F, Cl, Br, I, CF3, (CH2)m-C(O)Y1, benzyl and phenyl;
  • Figure US20170320878A1-20171109-C00005
  • wherein
  • R44 is selected from the group consisting of C1-10 alkyl, C1-4 alkoxy, OH, N(R10)R11, CN, NO, NO2, F, Cl, Br, I, CF3, (CH2)m-C(O)Y1, S(O))2R50;
  • with R10, R11, m, Y1 and R50 as defined above, also with all their embodiments.
  • Embodiments of the substituted ethene are propene, ethene-1,1-diyldibenzene and 3,3 -dimethylbut-1-ene.
  • An embodiment of substituted cyclohexene is 4-(cyclohex-1-en-1-yl)morpholine.
  • An embodiment of the substituted ethine is 1-octyne.
  • Preferably, Y is methyl or ethyl.
  • An embodiment of COMPSUBST is
  • Figure US20170320878A1-20171109-C00006
  • Y is methyl or ethyl, preferably ethyl.
  • The fluoro, chloro or fluorochloro alkylated compound is called compound ALKYLCOMPSUBST.
  • The fluoro, chloro and fluorochloro alkyl halide is compound FCLALKYLHALIDE.
  • Preferably, FCLALKYLHALIDE is a compound of formula (III);

  • R3-X  (III)
      • X is Cl, Br or I;
      • R3 is C1-20 alkyl or a C1-20 alkyl, wherein in the alkyl chain at least one of the hydrogens is substituted by F or Cl:
  • more preferably,
      • R3 is C1-15 alkyl or C1-15 alkyl, wherein in the alkyl chain at least one of the hydrogens is substituted by F or Cl;
  • even more preferably,
      • R3 is C1-10 alkyl or C1-10 alkyl, wherein in the alkyl chain at least one of the hydrogens is substituted by F or Cl.
  • Preferably,
      • X is Br or I;
  • more preferably,
      • X is I:
  • in another more preferably embodiment,
      • X is Br:
  • also with R3 in all its embodiments.
  • In an especial embodiment, compound FCLALKYLHADLIDE is a perfluoroalkyl halide,
      • F2HC—Cl or F2HC—Br, preferably FCLALKYLHADLIDE is a perfluoroalkylated bromide or iodide, F2HC—Cl or F2HC—Br;
  • preferably
      • X is Cl, Br or I, and
      • R3 is perfluoro C1-20 alkyl; or
      • FCLALKYLHADLIDE is F2HC—Cl or F2HC—Br;
  • more preferably,
      • X is Br or I, and
      • R3 is perfluoro C1-20 alkyl: or
      • FCLALKYLHADLIDE is F2HC—Cl or F2HC—Br;
  • even more preferably.
      • X is Br or I, and
      • R3 is perfluoro C1-15 alkyl; or
      • FCLALKYLHADLIDE is F2HC—Cl or F2HC—Br,
      • In particular, FCLALKYLHALIDE is selected from the group consisting of F21C10-I, F17C8-I, F13C6-I, F9C4-I, F3C—I, F3C—Br, F3C—Cl, F2HC—Cl, and F2HC—Br;
      • more in particular, FCLALKYLHALIDE is selected, from the group consisting of n-F21C10-I, n-F17C8-I, n-F13C6-I, n-F9C4-I, F3C—I, F3C—Br, F3C—Cl, F2HC—Cl, and F2HC—Br.
  • In one embodiment, the reaction is done in the presence of a compound COMPSALT;
      • COMPSALT is selected from the group consisting of NaI, KI, CsI and N(R30)(R31)(R32)R33I;
      • R30, R31, R32 and R33 are identical or different and independently from each other selected from the group consisting of H and C1-10 alkyl;
      • preferably, R30, R31, R32 and R33 are identical or different and independently from each other selected from the group consisting of H and C2-6 alkyl:
      • more preferably, COMPSALT is selected from the group consisting of NaI and (n-Bu)4NI.
      • The reaction is preferably done in the presence of a compound. COMPSALT and X is Cl or Br, preferably X is Cl.
  • Preferably, CAT is Pd(OAc)2.
  • Preferably, from 0.1 to 20 mol %, more preferably from 1 to 15 mol %, even more preferably from 2.5 to 12.5 mol %, of CAT are used in the reaction, the mol % are based on the molar amount of COMPSUBST.
  • Preferably, from 1 to 20 mol equivalents, more preferably 1 to 15 mol equivalents, even more preferably from 1 to 10 mol equivalents, of FCLALKYLHALIDE are used in the reaction, the mol equivalents are based on the molar amount of COMPSUBST.
  • In case of FCLALKYLHALIDE being in gaseous form, preferably FCLALKYLHALIDE was used in the reaction in an amount which corresponds to a pressure of from 1 to 10 bar, more preferably from 1 to 5 bar, at ambient temperature.
  • Preferably, from 1 to 40 mol %, more preferably 5 to 30 mol %, even more preferably from 5 to 25%, of BuPAd2 are used in the reaction, the mol % are based on the molar amount of COMPSUBST.
  • Preferably, from 0.1 to 10 mol equivalents, more preferably 0.5 to 5 mol equivalents, even more preferably from 0.75 to 2.5 mol equivalents, of TEMPO are used in the reaction, the mol equivalents are based on the molar amount of COMPSUBST.
  • Preferably, BAS is Cs2CO3.
  • Preferably, from 0.1 to 10 mol equivalents, more preferably 0.5 to 5 mol equivalents, even more preferably from 0.75 to 2.5 mol equivalents, of BAS are used in the reaction, the mol equivalents are based, on the molar amount of COMPSUBST.
  • The reaction temperature of the reaction is preferably from 20 to 200° C., more preferably from 50 to 200° C., even more preferably from 50 to 150° C., especially from 100 to 150° C., more especially from 110 to 145° C.
  • The reaction time of the reaction is preferably from 1 h to 60 h, more preferably from 10 h to 50 h, even more preferably from 15 h to 50 h.
  • Preferably, the reaction is done under inert atmosphere. Preferably, the inert atmosphere is achieved by the use if an inert gas preferably selected from the group consisting of argon, another noble gas, lower boiling alkane, nitrogen and mixtures thereof. The lower boiling alkane is preferably a C1-3 alkane, i.e. methane, ethane or propane.
  • The reaction can be done in a closed system, it can be done at a pressure caused by the chosen temperature in a closed system, and/or caused by the pressure applied by COMPSUBST, in case that COMPSUBST is in gaseous form. It is also possible to apply pressure with said inert gas. It Is also possible to carry out the reaction at ambient pressure.
  • The reaction can be done in a solvent SOL, SOL is preferably selected from the group consisting of alkanes. chlorinated alkanes, ketones, ethers, esters, aliphatic nitrils, aliphatic amides, sulfoxides, and mixtures thereof;
      • preferably SOL is selected from the group consisting of C5-8 alkane, chlorinated C5-8 alkane, acetone, methylethylketone, diethylketone, MTBE, tetrahydrofuran, methyltetrahydrofuran, ethylacetate, butylacetate, valeronitril, acetonitrile, dimethylformamide, dimethylacetamide, N-methylpyrrolidone, dimethylsulfoxide, and mixtures thereof;
      • more preferably SOL is selected from the group consisting of acetone, methylethylketone, diethylketone, valeronitril, acetonitrile, dimethylsulfoxide, and mixtures thereof;
      • even more preferably SOL is selected from the group consisting of acetone, methylethylketone, diethylketone, dimethylsulfoxide, and mixtures thereof.
  • It is also possible to use COMPSUBST simultaneously as substrate and as solvent.
  • As an alternative, the reaction can also be carried out in the absence of a solvent. In another embodiment, COMPSUBST is used as SOL.
  • The amount of SOL is preferably from 0.1 to 100 fold, more preferably from 1 to 50 fold, even more preferably from 1 to 25 fold, of the weight of COMPSUBST.
  • After the reaction, ALKYLCOMPSUBST can be isolated by standard methods such as evaporation of volatile components, extraction, washing, drying, concentration, crystallization, chromatography and any combination thereof, which are known per se to the person skilled in the art.
      • COMPSUBST, BAS, CAT, BuPAd2, TEMPO and FCLALKYLHALIDE, the fluoro, chloro and fluorochloro alkyl halide, are commercially available and can be prepared according to known procedures.
    EXAMPLES
  • Yield:
  • The yield is given in % as a molar yield of the expected ALKYLCOMPSUBST in the reaction mixture after the reaction, and is based on molar amount of COMPSUBST and was determined by 19F NMR with 1,4 difluorobenzene as internal standard, if not otherwise slated.
  • Isolated yield was derived from the weight of the isolated product and is based on the weight of COMPSUBST, isolated yield Is given in parenthesis in Table 1.
    • Ratio of Isomers and Position of Alkylation
  • were determined by NMR spectroscopy
    • Example 1
  • An oven-dried 4 mL vial with stir bar was charged with Pd(OAc)2 (10 mol %), BuPAd2 (20 mol %), TEMPO (1.0 eq), Cs2CO3 (2.0 eq), 1, 4 dimethoxybenzene (0.2 mmol, 1 eq). Then, acetone (0.5 mL) were injected into the vial under argon flow. The vial was placed in an alloy plate, which was transferred into a 300 mL autoclave of the 4560 series from Parr Instruments under an argon atmosphere. A pressure of 3 to 5 bar CF3Br followed by 15 bar of N2 was adjusted at ambient temperature. The reaction mixture was stirred at 130° C. for 40 h. After the reaction was finished, the autoclave was cooled down to room temperature and the pressure was released.
  • The reaction mixture was extracted with water and ethyl acetate (5 times, each time with 3 mL). The organic layers were washed with brine, dried over Na2SO4, and evaporated to yield the crude product. The yield was 81%.
  • The purification was done by flash chromatography on silica gel (eluent: heptanes:EtOAc=60:40 (v/v)). Isolated yield was 69%.
  • Details are also given in Table 1
    • Example 2
  • Example 1 repeated with the sole difference that Pd(TFA)2 was used as CAT instead of Pd(OAc)2). The yield was 78%.
    • Example 3
  • Example 1 repeated with the difference that only 5 mol % of Pd(OAc)2 were used instead of 10 mol %, and that only 10 mol % BuPAd2 were used instead of 20 mol %. The yield was 42%.
    • Example 4
  • Example 1 repeated with the sole difference that the reaction mixture was stirred at 130° C. for 30 h instead of 40 h. The yield was 70%.
    • Examples 5 to 21
  • Example 1 was repeated with the difference that as COMPSUBST the compound listed in Table 1 was used.
  • TABLE 1
    Yield
    (Ratio of
    Example COMPSUBST ALYKLCOMPSUBST Isomers)
     1
    Figure US20170320878A1-20171109-C00007
    Figure US20170320878A1-20171109-C00008
         		(69)
     5
    Figure US20170320878A1-20171109-C00009
    Figure US20170320878A1-20171109-C00010
         		(81)
     6
    Figure US20170320878A1-20171109-C00011
    Figure US20170320878A1-20171109-C00012
         		(76) (2:1 of a:b)
     7
    Figure US20170320878A1-20171109-C00013
    Figure US20170320878A1-20171109-C00014
         		(52)
     8
    Figure US20170320878A1-20171109-C00015
    Figure US20170320878A1-20171109-C00016
         		78 (3:1 of a:b)
     9
    Figure US20170320878A1-20171109-C00017
    Figure US20170320878A1-20171109-C00018
         		72
    10
    Figure US20170320878A1-20171109-C00019
    Figure US20170320878A1-20171109-C00020
         		61
    11
    Figure US20170320878A1-20171109-C00021
    Figure US20170320878A1-20171109-C00022
         		25
    12
    Figure US20170320878A1-20171109-C00023
    Figure US20170320878A1-20171109-C00024
         		53
    13
    Figure US20170320878A1-20171109-C00025
    Figure US20170320878A1-20171109-C00026
         		70 (2:1.2:1 of a:b:c)
    14
    Figure US20170320878A1-20171109-C00027
    Figure US20170320878A1-20171109-C00028
         		(47)
    15
    Figure US20170320878A1-20171109-C00029
    Figure US20170320878A1-20171109-C00030
         		(79)
    16
    Figure US20170320878A1-20171109-C00031
    Figure US20170320878A1-20171109-C00032
         		(76)
    17
    Figure US20170320878A1-20171109-C00033
    Figure US20170320878A1-20171109-C00034
         		80
    18
    Figure US20170320878A1-20171109-C00035
    Figure US20170320878A1-20171109-C00036
         		(64)
    19
    Figure US20170320878A1-20171109-C00037
    Figure US20170320878A1-20171109-C00038
    20
    Figure US20170320878A1-20171109-C00039
    Figure US20170320878A1-20171109-C00040
         		(61)
    21
    Figure US20170320878A1-20171109-C00041
    Figure US20170320878A1-20171109-C00042
         		(48)
    • Example 22
  • An oven-dried 4 mL vial with stir bar was charged with Pd(OAc)2 (10 mol %), BuPAd2 (20 mol %), TEMPO (1.0 eq), Cs2CO3 (2.0 eq), benzene (0.6 mmol, 1 eq) and perfluorohexyl bromide (3.2 eq). Then, acetone (2.5 mL) were injected into the vial under argon flow. The vial was placed in an alloy plate, which was transferred into a 300 mL autoclave of the 4560 series from Parr Instruments under an argon atmosphere. A pressure of 15 bar of N2 was adjusted at ambient temperature. The reaction mixture was stirred at 130° C. for 40 h. After the reaction was finished, the autoclave was cooled down to room temperature and the pressure was released.
  • The reaction mixture was extracted with water and ethyl acetate (5 times, each time with 3 mL). The organic layers were washed with brine, dried over Na2SO4, and evaporated to yield the crude product. The reaction mixture was analyzed by 19F-NMR by which an yield of 21% (perfluorohexyl)benzene was found. The identity of the (perfluorohexyl)benzene was confirmed by GC-MS.
  • A repetition of the experiment provided 28% yield with a conversion of 35%,
    • Example 23
  • An oven-dried 4 ml, vial with stir bar was charged with Pd(OAc)2 (10 mol %), BuPAd2 (20 mol %), TEMPO (1.0 eq), Cs2CO3 (2.0 eq), 1,4-dimethoxybenzene (0.2 mmol, 1 eq) and. perfluorohexyl bromide (3.2 eq). Then, acetone (1 mL) were injected into the vial under argon flow. The vial was placed in an alloy plate, which was transferred into a 300 mL autoclave of the 4560 series from Parr Instruments under an argon atmosphere. A pressure of 15 bar of N2 was adjusted at ambient temperature. The reaction mixture was stirred at 130° C. for 40 h.
  • After the reaction was finished, the autoclave was cooled down to room temperature and the pressure was released.
  • The reaction mixture was extracted with water and ethyl acetate (5 times, each time with 3 mL). The organic layers were washed with brine, dried over Na2SO4, and evaporated to yield the crude product. The reaction mixture was analyzed by GC-MS by which an yield of 42% 1,4-dimethoxy-2-(perfluorohexyl)benzene was found.
    • Example 24
  • An oven-dried 4 mL vial with stir bar was charged with Pd(OAc)2 (10 mol %), BuPAd2 (20 mol %), TEMPO (1.0 eq), Cs2CO3 (2.0 eq), ethene-1,1-diyldibenzene (0.5 mmol, 1 eq). Then, acetone (2 mL) were injected into the vial under argon flow. The vial was placed in an alloy plate, which was transferred into a 300 ml, autoclave of the 4560 series from Parr instruments under an argon atmosphere. A pressure of 3 to 5 bar CF3Br followed by 15 bar of N2 was adjusted at ambient temperature. The reaction mixture was stirred at 130° C. for 40 h. After the reaction was finished, the autoclave was cooled down to room temperature and the pressure was released.
  • The reaction mixture was filtered and the filter residue was washed with ethylacetate and acetone. The combined filtrates were concentrated on a rotary evaporator. The residue was purified by colomn chromatography on silica gel (eluent: heptanes:EtOAc=90:10 (v/v)).
  • Isolated yield was 58%.
  • 1H NMR Analysis of the obtained product showed a 2:1 mixture of (3,3,3-trifluoroprop-1-ene-1,1-diyl)dibenzene and (3,3,3-trifluoropropane-1,1-diyl)dibenzene. The identities of (3,3,3-trifluoroprop-1-ene-1,1 diyl)dibenzene and (3,3,3-trifluoropropane-1,1-diyl)dibenzene were confirmed by GC-MS.
    • Examples (Ex) 25 and 26 and Comparative Examples (CompEx) 1 to 10
  • Standard Procedure:
  • An oven-dried 4 mL vial with stir bar was charged with Pd(OAc)2 (10 mol %), BuPAd2 (20 mol %), ADDITIVE (1.0 eq), BASE (2.0 eq) and 1,4 dimethoxybenzene (0.2 mmol, 1 eq). Then, SOLVENT (0.5 mL) was injected into the vial under argon flow. The vial was placed in an alloy plate, which was transferred into a 300 mL autoclave of the 4560 series from Parr Instruments under an argon atmosphere. A pressure of 3 to 5 bar CF3Br followed by 15 bar of N2 was adjusted at ambient temperature. The reaction mixture was stirred at 130° C. for 40 h.
  • After the reaction was finished, the autoclave was cooled down to room temperature and the pressure was released.
  • The reaction mixture was extracted with water and ethyl acetate (5 times, each time with 3 mL). The organic layers were washed with brine, dried over Na2SO4, and evaporated to yield the crude product. The yield of the product was determined by 19F-NMR spectroscopy.
  • In CompEx 4 Pd(TFA)2 was used as CAT instead of Pd(OAc)2.
  • Table 2 shows the parameters that were tested.
  • TABLE 2
    YIELD
    ADDITIVE BASE SOLVENT (19F-NMR)
    CompEx 1 1,4-Benzoquinone Cs2CO3 Acetone 38%
    CompEx 2 Pivalic acid Cs2CO3 Acetone 31%
    CompEx 3 Ag2O Cs2CO3 Acetone 23%
    CompEx 4 TEMPO K2CO3 Acetone 35%
    CompEx 5 TEMPO Na2CO3 Acetone 42%
    Ex 25 TEMPO TEA Acetone 51%
    CompEx 6 TEMPO CsI Acetone 14%
    CompEx 7 TEMPO CsF Acetone 26%
    CompEx 8 TEMPO NaI Acetone 19%
    CompEx 9 TEMPO K3PO4 Acetone 4%
    CompEx 10 TEMPO K-tert. Acetone 39%
    butoxide
    Ex 26 TEMPO Cs2CO3 DMSO 74%
    • Example 27
  • Figure US20170320878A1-20171109-C00043
  • An oven-dried 4 ml, vial with stir bar was charged with Pd(OAc)2 (10 mol %), BuPAd2 (20 mol %), TEMPO (1 eq), Cs2CO3 (2.0 eq) and ethyl acrylate (0.5 mmol, 1 eq). Then, acetone (0,5 mL) were injected into the vial under argon flow sequentially. The vial was placed in an alloy plate, which was transferred into a 300 mL autoclave of the 4560 series from Parr Instruments under an argon atmosphere. A pressure of 3 to 5 bar CF3Br followed by 15 bar of N2 was adjusted at ambient temperature. The reaction mixture was stirred at 130° C. for 40 h. After the reaction was finished, the autoclave was cooled down to room temperature and the pressure was released.
  • The resulting reaction mixture was cooled, the pressure released from the autoclave, and the solids filtered. The filtered reaction mixture was analyzed by 19F-NMR using the internal standard 1,4-difluorobenzene showing an yield of 26% of ethyl4,4,4-trifluorobut-2enoat (delta 19F-NMR: -65.68 ppm (d, J=9.5 Hz)). GC-MS Analysis showed a molecular weight peak at 168 g/mol confirming monotrifluormethylation.
    • Comparative Example 11
  • Figure US20170320878A1-20171109-C00044
  • The entry 10 in Table 1 of Loy, R. N., et al, Organic Letters 2011, 13, 2548-2551, was repeated according to the detailed procedure given in the Supporting Information for said article, which is described under “Optimization procedure” on page S3 in connection with entry 9 in Table S4 on page S5.
  • The phosphine was BINAP.
  • [Pd] was Pd2dba3.
  • The base was Cs2CO3.
  • The alkylhalogenid was perfluorohexyl bromide instead of perfluorohexyl iodide.
  • To a screw cap 1 dram vial was added base (0.4 mmol, 2 equiv), [Pd] (0.02 mmol, 10 mol %) and phosphine (0.04-0.08 mmol, 20-40 mol %). Benzene (1 mL) and perfluorohexyl bromide (43 microl, 0.2 mmol, 1 equiv) were added, and the resulting mixture was sealed with a Teflon-lined cap and heated in an aluminum reaction block with vigorous stirring for 15 h at 80° C. The reaction mixture was cooled to 23° C. and chlorobenzene (20 microl,) was added as a GC internal standard. An aliquot (˜100 microL) was removed from the crude reaction mixture and passed through a plug of Celite, eluting with EtOAc (2 mL). This sample was then analyzed by GC, and the yield was determined by comparison to a calibration against the chlorobenzene internal standard.
  • Result:
  • A yield of less than 1% was measured.
    • Example 28
  • Figure US20170320878A1-20171109-C00045
  • A dried 50 mL autoclave was charged with 4-(cyclohex-1-en-1-yl)morpholine (0.2 mmol), Pd(OAc)2 (10 mol %), BuPAd2 (20 mol %), TEMPO (1.0), Cs2CO3 (2.0 equivalents). Then, acetone (2 ml) was injected into the autoclave and the autoclave was flushed with argon for 3 times. A pressure of 6 bar CF3Br followed by 15 bar of N2 was adjusted at ambient temperature. The reaction mixture was heated at 130° C. for 40 h. The autoclave was placed in a heating system and heated at 130° C. for 40 h. After the completion of the reaction, the autoclave was cooled down to room temperature and the pressure was released. 20 micdoL of 1,2 difluorobenzene (internal standard) was added to the reaction mixture and a sample was submitted for 19F NMR. The yield was measured by 19F NMR. The NMR data is in accordance with the literature N. V. Kirij et al., Journal of Fluorine Chemistry, 2000, 106, 217 to 221.

Claims (13)

1. A method for the preparation of a fluoro, chloro or fluorochloro alkylated compound by a reaction of a compound COMPSUBST with a compound FCLALKYLHALIDE by homogeneous catalysis using a catalyst CAT
in the presence of BuPAd2 and
in the presence of TEMPO and
in the presence of a compound BAS,
BAS is selected from the group consisting of Cs2CO3, CsHCO3, NEt3, and mixtures thereof;
FCLALKYLHALIDE is a compound of formula (III);

R3-X  (III)
X is Cl, Br or I;
R3 is C1-20 alkyl or a C1-20 alkyl, wherein in the alkyl chain at least one of the hydrogens is substituted by F or Cl;
CAT is selected from the group consisting of Pd(OAc)2, Pd(TFA)2, and mixtures thereof;
COMPSUBST is selected from the group consisting of a compound COMPSUBST-I, ethene, cyclohexene, ethine, and polystyrene;
the ethene and the cyclohexene being unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of C1-10 alkyl, C3-8 cycloalkyl. C1-4 alkoxy, N(R10)R11, CN, NO, NO2, F, Cl, Br, I, CF3, (CH2)m-C(O)Y1, S(O)2R50, CH═C(H)R28, C≡C-R24, benzyl, phenyl, naphthyl and morpholine;
the ethine being unsubstituted or substituted by 1 substituent selected from the group consisting of C1-10 alkyl, C3-8 cycloalkyl, C1-4 alkoxy, N(R10)R11, CN, NO, NO2, F, Cl, Br, I, CF3, (CH2)m-C(O)Y1, S(O)2R50, CH═C(H)R28, C≡C-R24 , benzyl, phenyl and naphthyl;
COMPSUBST-1 contains a ring RINGA;
RINGA is an unsaturated or aromatic, 5 or 6 membered carbocyclic or heterocyclic ring,
when RINGA is a heterocyclic ring, then RINGA has 1, 2 or 3 identical or different endocyclic heteroatoms independently from each other selected from the group consisting of N, O and S,
when RINGA is a 5 membered ring, then RINGA is unsubstituted or substituted by 1, 2, 3 or 4 identical or different substituents,
when RINGA is a 6 membered ring then RINGA is unsubstituted or substituted by 1, 2, 3, 4 or 5 identical or different substituents,
any of said substituents of RINGA is independently from any other of said substituent of RINGA selected from the group consisting of C1-10 alkyl, C3-8 cycloalkyl, C1-4 alkoxy, OH, N(R10)R11, CN, NH—OH, NO, NO2, F, Cl, Br, I, CF3, (CH2)m-C(O)Y1, S(O)2R50, CH═C(H)R28, C≡C-R24, benzyl, phenyl and naphthyl;
RINGA can be condensed with a ring RINGB, RINGB is a 5 or 6 membered carbocyclic or heterocyclic ring,
when RINGB is a heterocyclic ring, is contains 1, 2 or 3 identical or different endocyclic heteroatoms independently from each other selected from the group consisting of N, O and S;
RINGB is unsubstituted or substituted with 1, 2 or 3 in case of RINGB being a 5 membered ring, with 1, 2, 3 or 4 in case of RINGB being a 6 membered ring, identical or different substituents independently from each other selected from the group consisting of C1-10 alkyl, C3-8 cycloalkyl, C1-4 alkoxy, OH, N(R17)R18, CN, NH—OH, NO, NO2, F, Cl, Br, I, CF3, (CH2)n-C(O)Y2, S(O)2R51, CH═C(H)R38, C≡C-R34, benzyl, phenyl and naphthyl;
any of said C1-10 alkyl substituent of RINGA or RINGB is unsubstituted or substituted with 1, 2, 3, 4 or 5 identical or different substituents selected from the group consisting of halogen, OH, O—C(O)—C1-5 alkyl, O—C1-10 alkyl, S—C1-10 alkyl, S(O)—C1-10 alkyl, S(O2)—C1-10 alkyl, O—C1-6 alkylen-O—C1-6 alkyl, C3-8cycloalkyl and 1,2,4-triazolyl;
any of said benzyl, phenyl and naphthyl substituent of RINGA or RINGB is independently from each other unsubstituted or substituted with 1, 2, 3, 4 or 5 identical or different substituents selected from the group consisting of halogen, C1-4 alkoxy, NO2 and CN;
m, n and q are identical or different and independently from each other 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
Y1, Y2 and R13 are identical or different and independently from each other selected from the group consisting of H, OH, C(R14)(R15)R16, C1-6alkyl, O—C1-6 alkyl, phenyl, benzyl, O-phenyl, O—C1-6 alkylen-O—C1-6 alkyl and N(R19)R20;
R14, R15 and R16 are identical or different and independently from each other selected from the group consisting of H, F, Cl and Br;
R10, R11, R17, R18, R19 and R20 are identical or different and are independently from each other H or C1-6 alkyl, or R10 and R11, R17 and R18 or R19 and R20 represent together a tetramethylene or a pentamethylene chain;
R50 and R51 are identical or different and independently from each other selected from the group consisting of OH, C1-6 alkyl and C1-6 alkoxy;
R34, R34, R28 and R38 are identical or different and independently from each other selected from the group consisting of H, C1-10 alkyl, C(R25)(R26)—O—R27;
R25, R26 and R27 are identical or different and independently from each other selected from the group consisting of H and C1-10 alkyl,
2. The method according to claim 1, wherein
COMPSUBST is selected from the group consisting of compound COMPSUBST-I, ethene, cyclohexene, ethine, and polystyrene;
the ethene and the cydohexene being unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of C1-10 alkyl, C3-6 cycloalkyl, C1-4 alkoxy, N(R10)R11, CN, F, Cl, Br, I, CF3, (CH2)mC(O)Y1, S(O)2R50, benzyl, phenyl, naphthyl and morpholine;
the ethine being unsubstituted or substituted by 1 substituent selected from the group consisting of C1-10 alkyl, C3-6 cycloalkyl, C1-4 alkoxy, N(R10)R11, CN, F, Cl, Br, I, CF3, (CH2)m-C(O)Y1, S(O)2R50, benzyl, phenyl and naphthyl;
with COMPSUBST-I being selected from the group consisting of t,70
with COMPSUBST-I being unsubstituted or substituted
Figure US20170320878A1-20171109-C00046
by 1, 2, 3 or 4 in case of COMPSUBST-I being a monocyclic compound with 5 endocyclic atoms,
by 1, 2, 3, 4 or 5 in case of COMPSUBST-I being a monocyclic compound with 6 endocyclic atoms,
by 1, 2, 3, 4, 5 or 6 in case of COMPSUBST-I being a bicyclic compound wherein a 5-membered and a 6-membered ring are ortho-fused,
by 1, 2, 3, 4, 5, 6 or 7 in case of COMPSUBST-I being a bicyclic compound wherein two 6-membered rings are ortho-fused,
identical or different substituents independently from each other selected from the group consisting of C1-10 alkyl, C3-8 cycloalkyl, C1-4 alkoxy, OH, C(H)═O, N(R10)R11, CN, NH—OH, NO, NO2, F, Cl, Br, I, CF3, (CH2)m-C(O)Y1, S(O)2R50, CH═C(H)R28, C≡C-R24; benzyl, phenyl and naphthyl;
said C1-10 alkyl substituent of COMPSUBST-I is unsubstituted or substituted with 1, 2, 3, 4 or 5 identical or different substituents selected from the group consisting of halogen, OH, O—C(O)—C1-5 alkyl O—C1-10 alkyl, S—C1-10 alkyl, S(O)—C1-10 alkyl, S(O2)—C1-10 alkyl, O—C1-6 alkylen-O—C1-6 alkyl, C3-8 cycloalkyl and 1,2,4-triazolyl;
said benzyl, phenyl and naphthyl substituent of COMPSUBST-I is independently from each other unsubstituted or substituted with 1, 2, 3, 4 or 5 identical or different substituents selected from the group consisting of halogen, C1-4 alkoxy, NO2 and CN.
3. The method according to claim 1, wherein m, n and q are identical or different and independently from each other 0, 1, 2, 3 or 4.
4. The method according to claim 1, wherein
COMPSUBST is selected from the group consisting of benzene, pyrazole,
Figure US20170320878A1-20171109-C00047
Figure US20170320878A1-20171109-C00048
Figure US20170320878A1-20171109-C00049
compound of formula (VI), ethene, cyclohexene, ethine, and polystyrene;
Y is C1-6 alkyl:
the ethene and the cyclohexene being unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of C1-10 alkyl, C1-4 alkoxy, N(R10)R11, CN, F, Cl, Br, I, CF3, (CH2)m—C(O)Y1, benzyl, phenyl and morpholine;
the ethine being unsubstituted or substituted by 1 substituent selected from the group consisting of C1-10 alkyl, C1-4 alkoxy, N(R10)R11, CN, F, Cl, Br, I, CF3, (CH2)m-C(O)Y1, benzyl and phenyl;
Figure US20170320878A1-20171109-C00050
wherein
R44 is selected from the group consisting of C1-10 alkyl, C1-4 alkoxy, OH, N(R10)R11, CN, NO, NO2, F, Cl, Br, I, CF3, (CH2)m-C(O)Y1, S(O)2R50.
5. The method according to claim 1, wherein
X is Br or 1.
6. The method according to claim 1, wherein
X is Br.
7. The method according to claim 1, wherein compound FCLALKYLHADLIDE is a perfluoroalkyl halide, F2HC—Cl or F2HC—Br.
8. The method according to claim 1, wherein
X is Cl, Br or I, and
R3 is perfluoro C1-20 alkyl, or
FCLALKYLHADLIDE is F2HC—Cl or F2HC—Br.
9. The method according to claim 1, wherein
FCLALKYLHALIDE is selected from the group consisting of F21C10-I F17C8-I, F13C6I, F9C4-I, F3C-I, F3C—Br, F3C—Cl, F2HC—Cl, and F2HC—Br.
10. The method according to claim 1, wherein
the reaction is done in the presence of a compound COMPSALT;
COMPSALT is selected from the group consisting of NaI, KI, CsI and N(R30)(R31)(R32)R33I;
R30, R31, R32 and R33 are identical or different and independently from each other selected from the group consisting of H and C1-10 alkyl.
11. The method according to claim 10, wherein
R30, R31, R32 and R33 are identical or different and independently from each other selected from the group consisting of H and C2-6 alkyl.
12. The method according to claim 10, wherein
COMPSALT is selected from the group consisting of NaI and (n-Bu)4NI.
13. The method according to claim 1, wherein
CAT is Pd(OAc)2.
US15/522,336 2014-11-07 2015-11-05 Method for preparation of fluoro, chloro and fluorochloro alkylated compounds by homogeneous catalysis Active US9809596B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/522,336 US9809596B1 (en) 2014-11-07 2015-11-05 Method for preparation of fluoro, chloro and fluorochloro alkylated compounds by homogeneous catalysis

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201462076618P 2014-11-07 2014-11-07
EP14192280.7 2014-11-07
EP14192280 2014-11-07
EP14192280 2014-11-07
EP15181003 2015-08-13
EP15181003.3 2015-08-13
EP15181003 2015-08-13
EP15181019.9 2015-08-14
EP15181019 2015-08-14
EP15181019 2015-08-14
US15/522,336 US9809596B1 (en) 2014-11-07 2015-11-05 Method for preparation of fluoro, chloro and fluorochloro alkylated compounds by homogeneous catalysis
PCT/EP2015/075763 WO2016071425A1 (en) 2014-11-07 2015-11-05 Method for preparation of fluoro, chloro and fluorochloro alkylated compounds by homogeneous catalysis

Publications (2)

Publication Number Publication Date
US9809596B1 US9809596B1 (en) 2017-11-07
US20170320878A1 true US20170320878A1 (en) 2017-11-09

Family

ID=55908629

Family Applications (1)

Application Number Title Priority Date Filing Date
US15/522,336 Active US9809596B1 (en) 2014-11-07 2015-11-05 Method for preparation of fluoro, chloro and fluorochloro alkylated compounds by homogeneous catalysis

Country Status (9)

Country Link
US (1) US9809596B1 (en)
EP (1) EP3215476B1 (en)
JP (1) JP6240364B2 (en)
KR (1) KR101810378B1 (en)
CN (1) CN107108390B (en)
CA (1) CA2966791C (en)
MX (1) MX2017006020A (en)
TW (1) TW201630852A (en)
WO (1) WO2016071425A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3070021A1 (en) * 2017-07-28 2019-01-31 Lonza Ltd Method for preparation of alkylated or fluoro, chloro and fluorochloro alkylated compounds by heterogeneous cobalt catalysis
WO2019020726A1 (en) * 2017-07-28 2019-01-31 Lonza Ltd Method for preparation of alkylated or fluoro, chloro and fluorochloro alkylated compounds by heterogeneous cobalt catalysis
CN114206835A (en) * 2019-06-12 2022-03-18 阿尔萨达股份公司 Process for fluoroalkylating enamines
CN117430542B (en) * 2023-12-21 2024-03-08 上海恩氟佳科技有限公司 Synthesis method of trifluoromethyl indole derivative

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804955B1 (en) * 2000-02-11 2003-02-14 Rhodia Chimie Sa METHOD FOR FUNCTIONALIZING A DOUBLE LINK
JP5284037B2 (en) * 2008-10-30 2013-09-11 保土谷化学工業株式会社 Method for producing bisarylamine derivative
JP5764133B2 (en) * 2010-09-03 2015-08-12 大日本住友製薬株式会社 Cyclic amide derivative
KR20150013563A (en) * 2012-04-24 2015-02-05 추가이 세이야쿠 가부시키가이샤 Benzamide derivative

Also Published As

Publication number Publication date
MX2017006020A (en) 2017-06-19
CN107108390B (en) 2018-09-14
JP6240364B2 (en) 2017-11-29
CA2966791C (en) 2018-07-24
CN107108390A (en) 2017-08-29
JP2017533916A (en) 2017-11-16
CA2966791A1 (en) 2016-05-12
KR20170056017A (en) 2017-05-22
WO2016071425A1 (en) 2016-05-12
TW201630852A (en) 2016-09-01
US9809596B1 (en) 2017-11-07
KR101810378B1 (en) 2017-12-20
EP3215476B1 (en) 2018-02-28
EP3215476A1 (en) 2017-09-13

Similar Documents

Publication Publication Date Title
US9809596B1 (en) Method for preparation of fluoro, chloro and fluorochloro alkylated compounds by homogeneous catalysis
JP6851149B2 (en) Method for producing piperidine compound
JP6203431B2 (en) Process for preparing alkylated or fluoro, chloro and fluorochloroalkylated compounds by heterogeneous catalysis
JP7049604B2 (en) Method for Producing Pentafluorosulfanyl Aromatic Compound
US20040092781A1 (en) Preparation of polyhaloalkanes
EP3911658B1 (en) Method for preparation of fluoro alkylated compounds by homogeneous ni catalysis
EP3645484B1 (en) Method for preparation of alkylated or fluoro, chloro and fluorochloro alkylated compounds by heterogeneous cobalt catalysis
WO2020249759A1 (en) Method for fluoroalkylation of enamines
JP2012193124A (en) Method for producing 2,3-dichloropyridine
WO2019020726A1 (en) Method for preparation of alkylated or fluoro, chloro and fluorochloro alkylated compounds by heterogeneous cobalt catalysis
US11332456B2 (en) Method for preparation of fluoro alkylated 1,4-dioxene by homogeneous Ni catalysis
Rondestvedt Jr Meerwein arylation of fluorinated olefins
KR20030029973A (en) Process and Intermediate Compounds for the Preparation of Pesticidal Fluoroolefin Compounds
HU201527B (en) Process for producing substituted (dichloromethyl)-pyridines
Olivares Polyfluorinated systems resulting from free radical addition reactions

Legal Events

Date Code Title Description
AS Assignment

Owner name: LONZA LTD., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAESCHLER, CHRISTOPH;ZARAGOZA DOERWALD, FLORENCIO;ELLINGER, STEFAN;AND OTHERS;SIGNING DATES FROM 20170502 TO 20170508;REEL/FRAME:042715/0684

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: LONZA SOLUTIONS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LONZA LTD (ALSO KNOWN AS LONZA AG);REEL/FRAME:053453/0437

Effective date: 20200803

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4

AS Assignment

Owner name: ARXADA AG, SWITZERLAND

Free format text: CHANGE OF NAME;ASSIGNOR:LONZA SOLUTIONS AG;REEL/FRAME:058414/0403

Effective date: 20210928